Actinium Pharmaceuticals, Inc. (ATNM) has a consensus analyst rating of Buy, based on 11 analysts covering the stock. Of those, 11 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for ATNM is $11.07, representing a +906.4% upside from the current price of $1.1. Price targets range from a low of $4.00 to a high of $24.26.
